Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
EPB41L5 (erythrocyte membrane protein band 4.1 like 5) gene localization with human chromosome 2q14.2. This gene encodes the EPB41L5 protein, also known as BE37, YMO1. EPB41L5 is the first protein found in cytoskeleton and cell movement found in November 2007 and is widely expressed in the mesoderm and endoderm epithelial tissues of mammalian embryos. The dysregulation of EPB41L5 protein expression is closely related to the occurrence of some tumors.
Biological Function of EPB41L5
EPB41L5 belongs to the 4.1 protein family, which has a FERM domain at the N-terminus but lacks an actin-binding site at the C-terminus. The Band4.1 family is a very popular connexin family. Its large members of the family can participate in signal transduction. They also can connect with membrane proteins and cytosolic proteins (such as actin) of cells to exert stable cell structure.
EPB41L5 is involved in the development of the body and can play a role in TGF-β-induced EMT transformation by regulating the expression of downstream cadherin E-cadherin. The FERRM of EPB41L5 can interact with MPP5, CRB2, and CRB3 to form a CRB-MPP5-EPB41L5 complex. The complex can regulate a variety of cell adhesion factors, plays an important role in the tight junction between cells and the formation of cell polarity. Moreover, it is closely related to epithelial cell polarity and basement membrane formation. The FERM domain contained in EPB41L5 can cross-link with myosins protein containing MyThin tail homology 4 domain, and participate in cell pseudopod formation and cell movement. It also can bind to cytoskeletal proteins Talinl, PTK, and regulate cell actin skeleton.
When TGF-β stimulates cells, it up-regulates the expression of EPB41L5 and stimulates EMT. This process is mainly through up-regulation of EPB41L5, which competes with cell adhesion molecule E-cadherin for binding to p120-catenin, thereby reducing the cell surface adhesion molecule e-cadherin, which leads to cell separation. EPB41L5 enhances cell motility by enhancing adhesion spots at its C-terminus. In addition, EPB41L5 regulates the contractility of actomyosin by directly recruiting the small GTPase ARHGEF18, thereby affecting the focal adhesome (FA) maturation. This process is influenced by the composition of the extracellular matrix (ECM) and the potential regulation of collagen receptor mediated..
Figure 1. ECM influences EPB41L5-mediated phenotypes. (Schell C, et al. 2017)
EPB41L5 and Tumor
Studies have shown that EPB41L5 protein is highly expressed in the highly invasive renal clear cell carcinoma cell line 786-O and breast cancer cells MDA-MB-23. EPB41L5 protein forms Arf6-AMAP1-EPB41L5 complex with Arf6 and AMAP1 to Promote the invasion and metastasis of renal cancer cells to the stroma. The study found that EPB41L5 is also involved in the migration and invasion of tumor cells during cancer pathogenesis. Studies have reported a high correlation between EPB41L5 and lymph node metastasis in patients with head and neck squamous cell carcinoma and survival after surgery. Daimon et al. confirmed that the expression level of EPB41L5 was significantly increased in the translocation tissues of upper urinary tract cell carcinoma, and the highly expressed EPB41L5 was positively correlated with tumor grade, pathological stage, and tumor cell invasion.
The bioinformatics analysis and luciferase reporter gene assay confirmed that EPB41L5 was the target gene of miR-184, and the expression level of EPB41L5 was significantly decreased in renal cancer cells overexpressing miR-184. After EPB41L5 was silenced, the survival and migration ability of renal cancer cells was significantly decreased, indicating that the inhibitory effect of miR-184 on renal cell survival was achieved by regulating its target gene EPB41L5.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.